Enhertu+Pertuzumab CHMP: 44% Risk Cut in HER2 Breast Cancer

The EMA’s CHMP recommended approval of Enhertu (trastuzumab deruxtecan) plus pertuzumab as first-line treatment for adults with unresectable or metastatic HER2-positive breast cancer on July 24, 2026. The positive opinion moves the regimen closer to EU approval roughly seven months after the FDA cleared the same combination on December 15, 2025.

AstraZeneca (AZN) closed at $169.26 on July 24, with a market cap near $263 billion. Daiichi Sankyo, co-developer and ADR ticker DSNPY, trades OTC with limited US volume. The CHMP opinion is a revenue expansion event, not a stock-moving catalyst for a mega-cap, but it locks in EU market access for this regimen.

What the data showed

The recommendation is based on the Phase 3 DESTINY-Breast09 trial, which randomized 1,157 patients 1:1:1 to Enhertu monotherapy, Enhertu plus pertuzumab, or the current standard of care THP (taxane, trastuzumab, pertuzumab). The primary endpoint was progression-free survival by blinded independent central review.

The combination arm delivered a 44% reduction in the risk of disease progression or death versus THP (hazard ratio 0.56, 95% CI 0.44 to 0.71, p<0.00001). Median PFS was 40.7 months with Enhertu plus pertuzumab compared to 26.9 months with THP. That is nearly 14 additional months of median progression-free survival in the first-line setting, a margin that essentially closes the debate over which regimen oncologists should start with.

The trial was presented at the 2025 ASCO Annual Meeting and published in The New England Journal of Medicine.

Why this matters

Enhertu is a HER2-directed antibody-drug conjugate: a trastuzumab antibody linked to a topoisomerase I inhibitor payload (DXd) via a cleavable peptide linker. The ADC binds HER2 on the tumor cell, is internalized, and releases the cytotoxic payload inside the cell. The “bystander effect,” where released payload diffuses to neighboring tumor cells regardless of HER2 expression, is what gives Enhertu activity even in HER2-low disease.

HER2-positive breast cancer accounts for 15% to 20% of metastatic cases. The standard first-line regimen for over a decade has been THP. A 40.7-month median PFS in first-line metastatic disease is a result that redefines expectations for this patient population, where median survival historically ranged from 18 to 24 months on older regimens.

The safety profile in DESTINY-Breast09 was consistent with the known profiles of each drug, with no new safety signals. Interstitial lung disease and pneumonitis remain the key risks for Enhertu, with grade 1-2 ILD incidence around 11.6% in earlier trials. Oncologists manage this with active monitoring and dose holds, but it constrains use.

Competitive context

The EU approval expands Enhertu’s reach into a market where it already competes with Roche’s Kadcyla and the older trastuzumab-based regimens. The Trodelvy plus Keytruda CHMP opinion in first-line TNBC, covered separately, shows how the ADC class is moving earlier in the treatment sequence across breast cancer subtypes.

What to watch

The European Commission typically follows CHMP within 67 days, so EU approval should land by late September. The same July CHMP meeting that backed Enhertu also produced positive opinions for Trodelvy plus Keytruda in TNBC and Shionogi’s oral COVID-19 prophylactic. Watch for pricing and reimbursement negotiations in Germany and the UK, which often gate real-world uptake. The AstraZeneca press release and Daiichi Sankyo release are the primary sources.

The risk factor: Enhertu’s ILD safety signal limits how aggressively oncologists can combine it with other agents, and EU reimbursement timelines can stretch well beyond the EC decision.

What It Means for the Trade

For AZN and DSNKY holders, this is franchise-lock-in, not a stock event — a $263 billion mega-cap and its Japanese partner do not re-rate on an EU regulatory step. The trading relevance is in what the CHMP opinion confirms about the DESTINY-Breast09 data’s durability: a 44% risk reduction (HR 0.56) and a 40.7-month median PFS against THP in the first-line setting is a generational result, and it is now cleared in the U.S. (December 2025) with EU approval expected within roughly 67 days. That timing matters for revenue recognition: the first-line HER2-positive population is the largest single treatment bucket in this cancer type, and switching the global standard away from a taxane-plus-antibody regimen toward an ADC-plus-antibody regimen rewrites Enhertu’s peak-sales math more than any later-line expansion did. The EU decision also means the two largest oncology markets are now aligned, which de-risks the rest of the rolling global filings.

The competitive angle is what makes this worth watching even at mega-cap scale: DESTINY-Breast09 did not just beat THP, it also included an Enhertu monotherapy arm, and the combination’s first-line win sets the template for how ADCs displace antibody regimens across breast cancer — the same dynamic the Trodelvy/Keytruda first-line TNBC opinion is running in parallel. The Enhertu franchise is becoming the proof-of-concept that the entire ADC class trades on, with read-throughs to every company building HER2 or HER2-adjacent conjugates.

Mechanism and Trial Context

The regimen logic deserves scrutiny because “ADC plus antibody” is not an obvious combination. Enhertu’s trastuzumab backbone already engages the HER2 receptor; adding pertuzumab — which blocks HER2 dimerization at a different receptor domain — theoretically deepens pathway shutdown while the ADC payload delivers cell-killing. The concern with combining anti-HER2 agents is overlapping cardiac toxicity and additive ILD risk; DESTINY-Breast09 reported no new safety signals and a profile consistent with each drug’s known effects, with ILD remaining the class’s key management issue (roughly 11.6% grade 1-2 incidence in earlier trials). Oncologists will still monitor aggressively, and that monitoring burden — plus ILD-driven dose holds — is the practical friction that keeps some patients on THP despite the PFS math. The 40.7-month number wins the guideline argument; the ILD logistics shape the real-world adoption curve.

The three-arm design was quietly important for a second reason: Enhertu monotherapy versus the combination gives a clean internal read on how much pertuzumab actually adds. The NEJM publication of the full dataset is where analysts should scrutinize the combination-versus-monotherapy hazard ratio, because if the delta is modest, the cost-effectiveness conversation in EU reimbursement (where pertuzumab biosimilar pressure is real) gets more interesting.

Risks and What Could Go Wrong

1. EU reimbursement friction: EC approval is step one; Germany’s IQWiG and the UK’s NICE can stretch access timelines by quarters, and pricing negotiations against an established THP standard (with biosimilar trastuzumab and pertuzumab pressure) will compress Enhertu’s EU margin per patient.
2. ILD management: any evolution of the ILD signal in broader first-line use — a fitter population treated for longer — could constrain the label’s practical ceiling even if the trial data stays clean.
3. The OS question: PFS of 40.7 months is spectacular, but THP crossover muddies the eventual overall-survival read, and EU payers increasingly ask for survival economics.
4. Class crowding: the ADC wave Enhertu leads is also the ADC wave chasing it — next-generation HER2 conjugates and biosimilar trastuzumab deruxtecan eventually arrive; the patent clock, not the data, becomes the binding constraint.

Position read: for AZN this is one more block in the oncology franchise wall; the trade is watching quarterly Enhertu revenue for the first-line uptake slope and the EU pricing outcomes in Germany first. Nothing here changes position sizing — it changes conviction on the franchise’s trajectory.